Salmeterol/Fluticasone Propionate A Review of its Use in Asthma

被引:33
作者
McKeage, Kate [1 ]
Keam, Susan J. [1 ]
机构
[1] Adis Int Ltd, Wolters Kluwer Hlth, Auckland 0754, New Zealand
关键词
METERED-DOSE INHALER; FLUTICASONE PROPIONATE/SALMETEROL COMBINATION; TO-MODERATE ASTHMA; SHORT-ACTING BETA(2)-AGONISTS; MILD PERSISTENT ASTHMA; DRY POWDER INHALER; QUALITY-OF-LIFE; 250; MU-G; DOUBLE-BLIND; COST-EFFECTIVENESS;
D O I
10.2165/11202210-000000000-00000
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Salmeterol/fluticasone propionate (Seretide/Advair Diskus (R) [dry powder inhaler] or Seretide/Advair (R) inhalation aerosol [metered-dose inhaler]) is a fixed-dose combination inhalation agent containing a long-acting beta(2)-adrenoceptor agonist (LABA) plus a corticosteroid. In patients with symptomatic asthma, twice-daily salmeterol/fluticasone propionate maintenance therapy improves lung function and asthma symptoms to a greater extent than monotherapy with inhaled corticosteroids (ICS), such as fluticasone propionate, oral montelukast with or without fluticasone propionate, or sustained-release theophylline plus fluticasone propionate. The greater efficacy achieved with salmeterol/fluticasone propionate versus fluticasone propionate alone was sustained for I year in a well designed trial. Salmeterol/fluticasone propionate is also associated with a corticosteroid-sparing effect. Results of studies comparing fixed dosages of salmeterol/fluticasone propionate with formoterol/budesonide in adults and adolescents are equivocal. Twice-daily salmeterol/fluticasone propionate is associated with clinically meaningful improvements from baseline in health-related quality of life (HR-QOL), and improvements were greater than those reported with fluticasone propionate alone. Salmeterol/fluticasone propionate is generally well tolerated in adults, adolescents and children aged 4-11 years, and the fixed-combination inhaler ensures the appropriate use of a LABA in combination with an ICS. In cost-utility analyses in patients with uncontrolled asthma, salmeterol/fluticasone propionate compares favourably with fluticasone propionate alone or oral montelukast. Thus, salmeterol/fluticasone propionate provides an effective, well tolerated and cost-effective option for maintenance treatment in patients with asthma.
引用
收藏
页码:1799 / 1828
页数:30
相关论文
共 110 条
  • [91] Peters SP, 2007, NEW ENGL J MED, V356, P2027
  • [92] Salmeterol/fluticasone stable-dose treatment compared with formoterol/budesonide adjustable maintenance dosing: impact on health-related quality of life
    Price, David B.
    Williams, Angela E.
    Yoxall, Sally
    [J]. RESPIRATORY RESEARCH, 2007, 8
  • [93] National Institute for Clinical Excellence and its value judgments
    Rawlins, MD
    Culyer, AJ
    [J]. BRITISH MEDICAL JOURNAL, 2004, 329 (7459): : 224 - 227
  • [94] Inhaled salmeterol/fluticasone propionate - A review of its use in asthma
    Reynolds, NA
    Lyseng-Williamson, KA
    Wiseman, LR
    [J]. DRUGS, 2005, 65 (12) : 1715 - 1734
  • [95] The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma
    Ringdal, N
    Eliraz, A
    Pruzinec, P
    Weber, HH
    Mulder, PGH
    Akveld, M
    Bateman, ED
    [J]. RESPIRATORY MEDICINE, 2003, 97 (03) : 234 - 241
  • [96] Evaluation of different inhaled combination therapies (EDICT):: a randomised, double-blind comparison of Seretide™ (50/250 μg bd Diskus™ vs. formoterol (12 μg bd) and budesonide (800 μg bd) given concurrently (both via Turbuhaler™) in patients with moderate-to-severe asthma
    Ringdal, N
    Chuchalin, A
    Chovan, L
    Tudoric, N
    Maggi, E
    Whitehead, PJ
    [J]. RESPIRATORY MEDICINE, 2002, 96 (11) : 851 - 861
  • [97] Initiation of maintenance therapy with salmeterol/fluticasone propionate combination therapy in moderate asthma: A comparison with fluticasone propionate
    Rojas, Ramon A.
    Paluga, Igor
    Goldfrad, Caroline H.
    Duggan, Marie T.
    Barnes, Neil
    [J]. JOURNAL OF ASTHMA, 2007, 44 (06) : 437 - 441
  • [98] Combined salmeterol 50 μg and fluticasone propionate 250 μg in the Diskus device for the treatment of asthma.
    Shapiro, G
    Lumry, W
    Wolfe, J
    Given, J
    White, MV
    Woodring, A
    Baitinger, L
    House, K
    Prillaman, B
    Shah, T
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2000, 161 (02) : 527 - 534
  • [99] A cost-effectiveness analysis of first-line controller therapies for persistent asthma
    Shih, Ya-Chen Tina
    Mauskopf, Josephine
    Borker, Rohit
    [J]. PHARMACOECONOMICS, 2007, 25 (07) : 577 - 590
  • [100] Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: The Pediatric Asthma Controller Trial
    Sorkness, Christine A.
    Lemanske, Robert F., Jr.
    Mauger, David T.
    Boehmer, Susan J.
    Chinchilli, Vernon M.
    Martinez, Fernando D.
    Strunk, Robert C.
    Szefler, Stanley J.
    Zeiger, Robert S.
    Bacharier, Leonard B.
    Bloomberg, Gordon R.
    Covar, Ronina A.
    Guilbert, Theresa W.
    Heldt, Gregory
    Larsen, Gary
    Mellon, Michael H.
    Morgan, Wayne J.
    Moss, Mark H.
    Spahn, Joseph D.
    Taussig, Lynn M.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2007, 119 (01) : 64 - 72